Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.81 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | PLK1 | P53350 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11041909 | 0.90 | NPC1 (0.74) | NPC1L3MBTL1ALDH1A1LMNATP53 | |
| SCHEMBL19043463 | 0.85 | NPC1 (0.83) | NPC1L3MBTL1MMP1 | |
| SCHEMBL9657455 | 0.85 | NPC1 (0.83) | NPC1L3MBTL1ALDH1A1LMNATP53 | |
| SCHEMBL11041169 | 0.84 | THRA (0.68) | NPC1L3MBTL1TP53TSHRMMP1 | |
| SCHEMBL11825763 | 0.83 | NPC1 (0.81) | NPC1L3MBTL1ALDH1A1LMNATP53 | |
| SCHEMBL8098836 | 0.83 | NPC1 (0.87) | NPC1L3MBTL1ALDH1A1LMNATP53 | |
| SCHEMBL11263173 | 0.83 | NPC1 (0.81) | NPC1L3MBTL1 | |
| SCHEMBL7923674 | 0.83 | NPC1 (0.81) | NPC1L3MBTL1ALDH1A1LMNATP53 | |
| SCHEMBL20382633 | 0.82 | NPC1 (0.78) | NPC1L3MBTL1ALDH1A1LMNATP53 | |
| SCHEMBL4647638 | 0.81 | KMT2A (0.54) | NPC1L3MBTL1ALDH1A1LMNAPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957073-B1 | MEDICINAL DRUG | OTSUKA PHARMA CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| EP-2612858-A1 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-8263599-B2 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8188277-B2 | Aromatic compounds for suppressing the generation of collagen | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100210661-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2089373-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-19 | — | — | EP | disclosed |
| EP-1957073-A2 | MEDICINAL DRUG | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008044667-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-17 | — | — | WO | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |
| EP-1773797-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | NPC1 1029/4885L3MBTL1 502/4885ALDH1A1 565/4885 |
| US-20100210661-A1 | STAT3/5 ACTIVATION INHIBITOR | STAT3, JAK2, STAT1 | NPC1 4037/4885L3MBTL1 2478/4885ALDH1A1 1814/4885 |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | ROS1, CBR1, CBR3 | NPC1 1397/4885L3MBTL1 533/4885ALDH1A1 265/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | NPC1 2588/4885L3MBTL1 1465/4885ALDH1A1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.